This MYB activation is not limited to ACC cells, as other recognized targets for this gene, such as BIRC3, CDC2, and CXCR4, also show increased expression levels among MCF10A cells containing unchanged versions of both MYB and its fusion partner NFIB [20]. This evidence concerns the gene NFIB and adrenal cortex carcinoma.